These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 22685175)

  • 41. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
    Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
    Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
    Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia.
    Dou H; Chen X; Huang Y; Su Y; Lu L; Yu J; Yin Y; Bao L
    Genes Chromosomes Cancer; 2017 Feb; 56(2):135-146. PubMed ID: 27637012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Role of the JAK-STAT Pathway in Childhood B-Cell Acute Lymphoblastic Leukemia.
    Ziętara KJ; Wróblewska K; Zajączkowska M; Taczała J; Lejman M
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.
    Junco JJ; Zorman B; Gant VU; Muñoz J; Lacorazza HD; Sumazin P; Rabin KR
    Exp Hematol; 2022 Jun; 110():34-38. PubMed ID: 35306048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.
    Toosi B; Zaker F; Alikarami F; Kazemi A; Teremmahi Ardestanii M
    Biomed Pharmacother; 2018 Jun; 102():428-437. PubMed ID: 29574283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.
    Sarno J; Savino AM; Buracchi C; Palmi C; Pinto S; Bugarin C; Jager A; Bresolin S; Barber RC; Silvestri D; Israeli S; Dyer MJS; Cazzaniga G; Nolan GP; Biondi A; Davis KL; Gaipa G
    Oncotarget; 2018 May; 9(33):22872-22885. PubMed ID: 29796158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.
    Mediani L; Gibellini F; Bertacchini J; Frasson C; Bosco R; Accordi B; Basso G; Bonora M; Calabrò ML; Mattiolo A; Sgarbi G; Baracca A; Pinton P; Riva G; Rampazzo E; Petrizza L; Prodi L; Milani D; Luppi M; Potenza L; De Pol A; Cocco L; Capitani S; Marmiroli S
    Oncotarget; 2016 Feb; 7(5):5521-37. PubMed ID: 26575168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
    Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
    Mullighan CG; Collins-Underwood JR; Phillips LA; Loudin MG; Liu W; Zhang J; Ma J; Coustan-Smith E; Harvey RC; Willman CL; Mikhail FM; Meyer J; Carroll AJ; Williams RT; Cheng J; Heerema NA; Basso G; Pession A; Pui CH; Raimondi SC; Hunger SP; Downing JR; Carroll WL; Rabin KR
    Nat Genet; 2009 Nov; 41(11):1243-6. PubMed ID: 19838194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.
    Hanada I; Terui K; Ikeda F; Toki T; Kanezaki R; Sato T; Kamio T; Kudo K; Sasaki S; Takahashi Y; Hayashi Y; Inukai T; Kojima S; Koike K; Kosaka Y; Kobayashi M; Imaizumi M; Mitsui T; Hori H; Hara J; Horibe K; Nagai J; Goto H; Ito E
    Genes Chromosomes Cancer; 2014 Nov; 53(11):902-10. PubMed ID: 25044358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
    Madzio J; Pastorczak A; Sedek L; Braun M; Taha J; Wypyszczak K; Trelinska J; Lejman M; Muszynska-Roslan K; Tomasik B; Derwich K; Koltan A; Kazanowska B; Irga-Jaworska N; Badowska W; Matysiak M; Kowalczyk J; Styczynski J; Fendler W; Szczepanski T; Mlynarski W
    Genes Chromosomes Cancer; 2019 Sep; 58(9):619-626. PubMed ID: 30859636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TSLP signaling network revealed by SILAC-based phosphoproteomics.
    Zhong J; Kim MS; Chaerkady R; Wu X; Huang TC; Getnet D; Mitchell CJ; Palapetta SM; Sharma J; O'Meally RN; Cole RN; Yoda A; Moritz A; Loriaux MM; Rush J; Weinstock DM; Tyner JW; Pandey A
    Mol Cell Proteomics; 2012 Jun; 11(6):M112.017764. PubMed ID: 22345495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
    Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
    N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High occurrence of CRLF2 abnormalities in Mexican children with B-cell acute lymphoblastic leukemia.
    Juárez-Velázquez MDR; Moreno-Lorenzana DL; Martínez Anaya DA; Hernández Monterde EA; Aguilar-Hernández MM; Reyes-León A; Chávez-González MA; López Santiago N; Zapata Tarrés M; Juárez Villegas L; Rivera Sánchez N; Soto Lerma O; Vega-Vega L; Rivera Luna R; Pérez-Vera P
    Cytokine; 2022 Jul; 155():155896. PubMed ID: 35537330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
    Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
    Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical Features and Prognosis of Acute Lymphoblastic Leukemia Children with P2RY8-CRLF2 Gene Rearrangement].
    Zheng YZ; LE SH; Zheng H; Hua XL; Chen ZS; Zheng L; Chen C; Li M; Cai CX; Yang JH; Chen YQ; Gao QL; Chen YY; Li J; Hu JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):311-315. PubMed ID: 33812392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients.
    Vetter T; Borowski A; Wohlmann A; Ranjan N; Kuepper M; Badura S; Ottmann OG; Friedrich K
    Leuk Res; 2016 Jan; 40():38-43. PubMed ID: 26652578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.